Skip to main content

Table 1 Summary of treatment conditions on BV-2 and IMA2.1 cells and their effects on VACV infection

From: Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps

Treatment condition BV-2 IMA2.1 BV-2 IMA2.1
Virus progenya VACV-mediated cell deathb
M2 phenotype
 w/o + 0 +
 IL-4 + nt +
M1 phenotype
 IFN-γ
 IFN-γ + LPS
 LPS
  1. nt not tested, w/o without stimulation.
  2. aVirus progeny (24 and 72 hpi) related to the infection medium was determined by standard plaque assays. [+] indicates an increase of the virus titer from the infection medium, [0] virus titer at the same level as the infection medium, [−] virus titer below the infection medium.
  3. bVACV-mediated cell death was related to uninfected controls (24–72 hpi) and measured by MTT cell survival assays. [+] more than 50% of cells were killed by LIVP 1.1.1 [−] less than 50% of cells were killed by LIVP 1.1.1.